Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.

07/20/2026, 1:30 PM • The Motley Fool

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

The article compares two healthcare ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on concentrated U.S. pharma exposure with 29 holdings, and iShares Global Healthcare ETF (IXJ), which offers diversified global healthcare with 110 holdings. PJP delivered superior 1-year returns of 44.90% versus IXJ's 18.20%, though IXJ has a lower expense ratio (0.40% vs 0.57%) and higher dividend yield (1.50% vs 0.90%). The article recommends PJP for investors seeking healthcare exposure due to its stronger performance across most timeframes.

07/20/2026, 10:17 AM • The Motley Fool

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is positioning itself as a contender in the rapidly growing $100 billion weight-loss drug market through its acquisition of Metsera and development of promising GLP-1 candidates like MET-097i, which showed strong efficacy with potential monthly dosing. However, the company faces stiff competition from Eli Lilly and Novo Nordisk, who currently lead the market with more advanced triple agonist drugs. While Pfizer may not dominate the space, it is well-positioned to be a significant player, and the company has other growth drivers including oncology pipeline and a high dividend yield of 6.9%.

07/20/2026, 3:15 AM • The Motley Fool

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

The article compares two healthcare ETFs: IHE (U.S. Pharmaceuticals) and IXJ (Global Healthcare). IHE offers concentrated exposure to 56 U.S. pharmaceutical companies with higher recent returns (50.30% 1-yr), but carries significant concentration risk with its top two holdings (J&J and Eli Lilly) comprising 43% of the portfolio. IXJ provides broader diversification across 110 international healthcare companies including medical devices and services, with lower concentration risk but more modest recent returns (18.20% 1-yr). The article suggests IXJ is better for diversification-focused investors, while IHE's outperformance is largely driven by GLP-1 weight-loss drug success.

07/18/2026, 8:16 PM • The Motley Fool

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

While Eli Lilly's GLP-1 weight-loss drugs (Mounjaro and Zepbound) account for nearly two-thirds of revenues with strong growth, the company is strategically using profits from these drugs to build a diversified pipeline in immunology, oncology, and neuroscience through acquisitions like AtaiBeckley and Ventyx Biosciences. Non-weight-loss drugs are already showing 160% revenue growth, positioning Eli Lilly for long-term success beyond the limited patent life of GLP-1 drugs.

07/17/2026, 9:15 PM • The Motley Fool

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

07/17/2026, 2:30 PM • The Motley Fool

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

07/17/2026, 8:36 AM • GlobeNewswire

Why AtaiBeckley Stock Soared Today

AtaiBeckley shares surged 33.40% after pharmaceutical giant Eli Lilly agreed to acquire the mental health-focused biotechnology company for $6.75 per share in cash, plus up to $2.50 per share in milestone payments. The total deal valuation could reach approximately $3.8 billion if all conditions are met. The acquisition is expected to close in Q3, subject to shareholder and regulatory approval.

07/16/2026, 6:12 PM • The Motley Fool

Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF

The iShares Global Healthcare ETF (IXJ) outperformed the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) over the past five years, delivering stronger total returns (1.50% dividend yield vs. 0.70%), lower volatility (beta of 0.56 vs. 0.78), and a shallower maximum drawdown. While both funds charge identical 0.40% expense ratios, IXJ's market-cap weighting and international exposure of 110 global healthcare stocks provide broader diversification compared to RSPH's 60 U.S. large-cap equal-weighted holdings.

07/16/2026, 9:31 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech

As the market broadens beyond technology stocks, three Vanguard ETFs are positioned to benefit: the Healthcare ETF (VHT) is rallying on strong biotech and obesity drug prospects, the Value ETF (VTV) stands to gain as value stocks show renewed momentum after nearly two decades of underperformance, and the Small-Cap ETF (VB) is accelerating with attractive valuations and improving earnings estimates.

07/15/2026, 6:25 AM • The Motley Fool

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

07/15/2026, 4:15 AM • GlobeNewswire

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly's new oral weight loss drug Foundayo is showing concerning early signs with flat prescription growth over five weeks post-launch, significantly trailing Novo Nordisk's oral Wegovy. However, analysts note that Foundayo's slower start may be temporary due to later pharmacy coverage and being a new drug formulation, while Lilly maintains a strong 60% U.S. market share and deep pipeline in the rapidly growing weight loss drug market.

07/14/2026, 6:10 AM • The Motley Fool

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly's weight-loss and diabetes drugs Mounjaro and Zepbound generated $12.8 billion in Q1 2026 revenue, representing nearly two-thirds of the company's total revenue. Mounjaro showed accelerating growth at 125% year-over-year, while the company raised its 2026 guidance to $82-85 billion. The FDA approval of Foundayo, a once-daily GLP-1 pill, expands the franchise's market reach. However, the company's valuation heavily depends on this single drug family, presenting both significant opportunity and concentration risk.

07/13/2026, 4:23 AM • The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The article recommends three high-yield dividend stocks for the second half of 2026: Novo Nordisk (3.5% yield) is positioned to regain market share in GLP-1 drugs with its superior pill formulation despite pricing pressures; Realty Income (5% yield) offers stable, conservative dividend growth through its diversified net lease REIT portfolio; and Enterprise Products Partners (5.9% yield) provides reliable energy infrastructure income through a toll-taker model insulated from oil price volatility.

07/11/2026, 9:15 AM • The Motley Fool